ANDA 204463, held by SOFIE. Fludeoxyglucose F-18.
As of Nov 21, 2026, ANDA 204463 (Fludeoxyglucose F18), held by SOFIE, was first approved by FDA on Oct 21, 2014, with 1 approved supplement and 0 published complete response letters.
Fludeoxyglucose F18 Injection, USP is indicated for positron emission tomography (PET) imaging in the following settings:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 21, 2014 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Mar 1, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 21, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters